- October 26, 2026
- Category: Press release
Cachan, France | October, 2026
DOSIsoft, leading provider of patient-specific imaging and dosimetry software solutions for radiation oncology and nuclear medicine, announces the opening of its new offices within the Institut du Cancer de Montpellier (ICM). It reflects DOSIsoft’s long-term commitment to innovation, research, and close collaboration with leading cancer centers and research institutes to improve patient care.
This new location builds on a strong and ongoing collaboration with the Nuclear Medicine Department at ICM, headed by Prof. Pierre-Olivier Kotzki,, which began in 2018. Over the years, this partnership has already led to multiple joint clinical and research initiatives centered on PLANET – DOSIsoft’s flagship software platform for theranostics – a comprehensive platform with advanced voxel-based multi-radionuclide dosimetry capabilities and full multimodality DICOM interoperability.
Beyond its clinical collaboration with the Nuclear Medicine Department, DOSIsoft is also engaged in a strong research partnership with the Institut de Recherche en Cancérologie de Montpellier (IRCM), further reinforcing its scientific footprint within the Montpellier ecosystem. This includes collaboration with Manuel Bardiès, Research Director and internationally recognized expert in Molecular RadioTherapy (MRT) dosimetry, whose work contributes to advancing methodologies and innovation in the field. This dosimetry research project is notably driven by Dr. Lore Santoro, with Prof. Emmanuel Deshayes leading the clinical component.
Being located directly at ICM – Institut du Cancer de Montpellier, DOSIsoft is taking a significant step forward in reinforcing these complementary clinical and research collaborations. Such close proximity to clinicians and researchers will facilitate even closer interaction, enabling faster feedback between healthcare professionals, scientists, and developers, while ensuring that product evolution remains fully aligned with real-world clinical needs and cutting-edge research.
This environment will not only accelerate the ongoing development of the PLANET platform but also expand opportunities for new translational research projects bridging clinical practice and scientific innovation.
“Our collaboration with ICM and IRCM has already demonstrated the value of close partnerships between industry, clinicians, and researchers,” Marc Uszynski, CEO at DOSIsoft. “With these new offices, we are strengthening an already active and multi-faceted collaboration, creating the conditions to go even further—both in advancing our PLANET solution and in developing new clinical and scientific projects together.”
About PLANET
PLANET is a next-generation platform for personalized dosimetry in Molecular RadioTherapy (MRT) and Selective Internal Radiation Therapy (SIRT), designed to optimize treatment planning and improve patient outcomes through precision medicine. PLANET is a Class IIb CE-marked medical device under MDR (EU) 2017/745 and FDA 510(k) cleared.
About DOSIsoft
Founded in 2002, DOSIsoft is a market leader in dosimetry software for radiation oncology and nuclear medicine, dedicated to improving cancer treatment quality and patient safety. With more than 1,000 installations across 800+ hospital centers in 80 countries, DOSIsoft provides advanced solutions for radiation therapy quality assurance, theranostics, and personalized dosimetry. A spin-off from Gustave Roussy and Institut Curie, DOSIsoft continues to innovate through close collaboration with leading cancer centers worldwide. www.dosisoft.com
Press contact: Xiaolu CHEN | xiaolu.chen@dosisoft.com
About ICM
Founded in 1923, the Institut du Cancer de Montpellier (ICM) is the leading Comprehensive Cancer Center (Centre de Lutte Contre le Cancer – CLCC) in the Occitanie region. Nationally recognized for its expertise and innovation in cancer care, ICM is one of the 18 Comprehensive Cancer Centers within the Unicancer network. ICM is one of the few institutions in France to bring together cancer care, prevention, and clinical, translational and fundamental research on a single site. The Institute is authorized to receive donations, bequests and gifts to support and fund its projects. ICM in figures: 43,430 patients treated in 2025; 75,960 consultations; 1,283 employees, including 159 physicians and 292 researchers; and 19 joint research teams (Inserm/ICM/UM1).
Press contact : Nathan Roure | +33 (0)6 69 96 12 61 | nathan.roure@icm.unicancer.fr
About IRCM
The Montpellier Cancer Research Institute is a research center dedicated to understanding the mechanisms of cancer and developing new strategies to better prevent, diagnose, and treat the disease. Located at the heart of the Val d’Aurelle campus in Montpellier, the IRCM benefits from a unique environment that brings together research, innovation, and healthcare. With 19 research teams and 10 technological platforms, the IRCM brings together researchers, clinicians, engineers, technicians, PhD students, and students around a shared goal: advancing our understanding of cancer and contributing to the development of new solutions for patients. The institute also hosts two biotechnology companies and has access to high-tech platforms that support cutting-edge research.
Press contact : Inès Douillez | ines.douillez@inserm.fr